Skip to main content
OpenTrials
Completed

NCT Number: NCT06916091

A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much Eloralintide gets into the bloodstream and how long it takes the body to eliminate it.

The study will last approximately 10 weeks excluding a screening period.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Lilly Centre for Clinical Pharmacology

Singapore, 138623

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Chinese participants. To qualify as Chinese, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China
  • Have had a stable body weight for 3 months prior to screening. Participants with body weight change of less than 5% will be allowed
  • Have not modified diet or adopted any nutritional lifestyle modification for 3 months before randomization
  • Have clinical laboratory test results within a normal range for the population or investigative site at screening and lead-in, or results with acceptable deviations that are judged to be not clinically significant by the investigator
  • Have a body mass index (BMI) within the range 27 to 40 kilogram per square meter (kg/m²)

Exclusion criteria

  • Are pregnant, or intend to become pregnant or to breastfeed during the study
  • Have known allergies to related compounds of eloralintide
  • Have any of the following abnormal blood pressure (BP) and/or pulse rate at screening, constituting a risk when taking the investigational product with minor deviations judged to be acceptable by the investigator:
  • Supine BP > 160/90 millimeter mercury (mmHg)
  • Supine pulse rate < 50 or > 100 beats per minute (bpm)
  • Orthostatic hypotension
  • Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs
  • Regularly use known drugs of abuse and/or show positive findings on drug screening that are not consistent with the medical history or concomitant medication history
  • Have donated blood of more than 450 mL within the previous 3 months of study screening, or intend to donate blood during the course of the study
  • Have a history of chronic medical conditions involving the heart, liver, or kidneys
  • Have a medical history or current evidence of clinically significant cardiac condition

Treatment and study plan

Eloralintide

Drug

Administered subcutaneously (SC)

Other names: LY3841136

Placebo

Drug

Administered SC

Primary outcomes

  1. Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    Time frame: Baseline to Study Completion (Up to 10 Weeks)

    A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Eloralintide

    Time frame: Baseline to Study Completion (Up to 10 Weeks)

    PK:Cmax of Eloralintide

  2. PK: Area Under the Concentration Versus Time Curve (AUC) of Eloralintide

    Time frame: Baseline to Study Completion (Up to 10 Weeks)

    PK: AUC of Eloralintide

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Phase 1, Investigator- and Participant-Blinded, Placebo Controlled, Randomized, Single Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Apr 8, 2025
Registry last updated
Nov 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.